Venous Thromboembolism (VTE): Deep Vein Thrombosis and Pulmonary Embolism

1. Clinical Overview

Summary

Venous thromboembolism (VTE) encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE), representing a spectrum of the same pathological process. VTE affects nearly 10 million people worldwide annually and is a leading cause of preventable in-hospital death. [1] The pathophysiology follows Virchow's triad: venous stasis, endothelial injury, and hypercoagulability. DVT typically originates in the deep veins of the lower extremities, and approximately 50% of untreated proximal DVTs lead to PE when the thrombus embolizes to the pulmonary circulation. [2]

The clinical significance lies in both acute mortality (particularly from massive PE) and chronic morbidity from post-thrombotic syndrome (PTS) and chronic thromboembolic pulmonary hypertension (CTEPH). Modern management revolves around validated risk stratification tools (Wells score), D-dimer testing integrated with pretest probability, confirmatory imaging (compression ultrasonography for DVT, CT pulmonary angiography for PE), and evidence-based anticoagulation strategies. Direct oral anticoagulants (DOACs) have revolutionized treatment, offering similar efficacy to traditional warfarin with improved safety profiles and no requirement for routine monitoring. [3,4]

Critical management decisions include: (1) distinguishing provoked from unprovoked VTE to guide anticoagulation duration, (2) identifying patients requiring thrombolysis or catheter-directed interventions, (3) determining appropriate thrombophilia testing, and (4) balancing recurrence risk against bleeding risk for extended anticoagulation. Early diagnosis and prompt anticoagulation remain the cornerstone of treatment, reducing mortality from 25-30% to less than 5% in PE. [5]

Key Facts

• Definition: Formation of blood clot in deep venous system (DVT) or pulmonary arterial tree (PE)
• Annual incidence: 1-2 per 1,000 population for VTE; increases exponentially with age [1]
• Mortality:
  • "Untreated PE: 25-30%"
  • "Treated PE: 2-8%"
  • "Massive PE (with hemodynamic compromise): 15-25% despite treatment [5]"
• Recurrence risk:
  • "Provoked VTE (after stopping anticoagulation): 3-5% per year"
  • "Unprovoked VTE: 10% at 1 year, 30% at 5 years [6]"
• Peak age: Incidence increases exponentially after age 60; median age ~62 years
• Critical feature: Clinical diagnosis unreliable; objective testing mandatory
• Key investigation: Wells score + age-adjusted D-dimer for exclusion; compression ultrasound (DVT) or CTPA (PE) for confirmation
• First-line treatment: Anticoagulation with DOAC (rivaroxaban, apixaban, edoxaban, dabigatran) or LMWH bridging to warfarin [3,4]

Clinical Pearls

"Non-high pretest probability + negative D-dimer = VTE excluded" — This combination has > 99% negative predictive value. No imaging required. [2]

"Proximal DVT vs distal DVT matters" — Proximal DVT (popliteal or above) has 50% PE risk if untreated; isolated calf DVT has less than 5% PE risk. Treatment differs. [7]

"PESI score guides PE disposition" — Low-risk PE (PESI class I-II or sPESI = 0) can be managed as outpatient with proper infrastructure; saves costs without increasing mortality. [8]

"DOACs are NOT equal" — Rivaroxaban and apixaban are single-drug approaches; dabigatran and edoxaban require parenteral lead-in. Apixaban has lowest major bleeding rate. [3,4]

"Unprovoked VTE = minimum 3 months, consider indefinite" — After 3 months, reassess: men with unprovoked proximal DVT/PE have 10%/year recurrence risk off anticoagulation. Indefinite therapy often warranted if low bleeding risk. [6,9]

"Thrombophilia testing rarely changes management" — Most inherited thrombophilias don't independently warrant indefinite anticoagulation. Test only if results will alter duration (e.g., antithrombin deficiency, antiphospholipid syndrome). [10]

Why This Matters Clinically

VTE represents a critical intersection of emergency medicine, haematology, respiratory medicine, and vascular surgery. Missed PE is a leading cause of preventable in-hospital death and medical litigation. The condition exemplifies evidence-based medicine: we have validated diagnostic algorithms (Wells + D-dimer), robust imaging protocols, high-quality RCT evidence for anticoagulation (EINSTEIN, AMPLIFY, HOKUSAI trials), and risk stratification tools (PESI for PE, Villalta score for PTS prediction). [3,4,11]

The shift from warfarin to DOACs has transformed outpatient management, eliminating the need for bridging therapy and INR monitoring in most patients. However, critical decisions remain: determining anticoagulation duration requires balancing 10-30% recurrence risk against 1-3% major bleeding risk annually, with patient values central to shared decision-making. Recognition of provoked versus unprovoked VTE, cancer-associated thrombosis (CAT), and pregnancy-related VTE each require distinct management approaches. [6,9,12]

---

2. Epidemiology & Risk Factors

Incidence & Prevalence

VTE is the third most common acute cardiovascular syndrome after myocardial infarction and stroke. [1]

Overall Burden:

• Annual incidence: 1-2 per 1,000 population (Western populations)
• DVT:PE ratio: Approximately 2:1 (DVT more common)
• Recurrent VTE: 20-30% at 5 years for unprovoked events
• Fatal PE: Approximately 60,000-100,000 deaths annually in the United States [1]

Age Distribution:

• Age less than 40 years: less than 1 per 10,000/year
• Age 40-60 years: 1-2 per 1,000/year
• Age 60-80 years: 2-7 per 1,000/year
• Age > 80 years: 7-12 per 1,000/year
• Clinical pearl: VTE is exceedingly rare in children without major risk factors (malignancy, central lines, nephrotic syndrome)

Temporal Trends:

• Incidence: Stable or slightly increasing (possibly due to improved detection)
• Case fatality: Declining (improved anticoagulation, earlier diagnosis)
• Hospitalization rates: Decreasing (outpatient management with DOACs)

Demographics

Risk Factors: Virchow's Triad in Clinical Practice

VTE results from interaction between patient-specific factors (genetic, acquired) and exposures (surgery, immobility). Risk is cumulative and multiplicative. [2]

Strong Risk Factors (Odds Ratio > 10):

Moderate Risk Factors (Odds Ratio 2-9):

Weak/Minor Risk Factors (Odds Ratio less than 2):

• Obesity (BMI > 30 kg/m²): RR 2-3×
• Smoking: RR 1.5-2×
• Varicose veins: RR 1.5×
• Prolonged air travel (less than 4 hours): RR ~1.5×

Inherited Thrombophilias

Account for 30-50% of unprovoked VTE, but testing rarely alters management. [10]

ASH 2023 Guidance on Thrombophilia Testing: [10]

• ❌ Do NOT test routinely after first provoked VTE
• ❌ Do NOT test general population before oral contraceptives
• ✅ Consider testing if:
  • Unprovoked VTE in young patient (less than 50 years) with strong family history
  • Recurrent unprovoked VTE
  • Unusual site thrombosis (cerebral, mesenteric, portal vein)
  • Suspected antiphospholipid syndrome
• Key principle: Test only if result will change management (duration/intensity of anticoagulation or family counseling)

Provoked vs Unprovoked VTE: Critical Distinction

This classification is the single most important factor determining anticoagulation duration. [6,9]

Provoked VTE = VTE occurring in the presence of a transient or reversible risk factor within 3 months:

Major Transient Risk Factors (low recurrence risk after stopping anticoagulation):

• Surgery with general anesthesia > 30 minutes
• Hospitalization for acute medical illness with immobility > 3 days
• Major trauma
• Cesarean section

Minor Transient Risk Factors (intermediate recurrence risk):

• Estrogen therapy (COC, HRT)
• Pregnancy/postpartum
• Minor surgery or trauma
• Prolonged travel (> 6-8 hours)

Persistent Risk Factors (ongoing elevated risk):

• Active cancer
• Inflammatory bowel disease (active)
• Autoimmune disease

Unprovoked VTE = VTE with no identifiable transient or persistent risk factor, OR occurring with minor/persistent risk factors.

Recurrence Risk After Stopping Anticoagulation: [6,9]

• Surgery-provoked: 1% at 1 year, 3% at 5 years → Anticoagulate 3 months only
• Non-surgical major transient: 5% at 1 year, 15% at 5 years → Anticoagulate 3 months, consider extension
• Unprovoked: 10% at 1 year, 30% at 5 years → Consider indefinite anticoagulation
• Cancer-associated: 15% at 1 year, > 40% at 5 years → Anticoagulate while cancer active

---

3. Pathophysiology

Virchow's Triad: Molecular to Macroscopic

The pathogenesis of VTE reflects Rudolf Virchow's 1856 triad, now understood at molecular and cellular levels.

1. Venous Stasis (Hemodynamic Changes)

Mechanisms:

• Reduced venous blood flow → accumulation of activated clotting factors (failure to clear)
• Reduced shear stress → endothelial dysfunction, reduced prostacyclin and nitric oxide
• Hypoxia in valve pockets → pro-inflammatory state, leukocyte adhesion
• Valve sinus stasis → primary site for thrombus formation (90% of DVTs originate at venous valve sinuses)

Clinical scenarios:

• Immobility: Long-haul travel, bedrest, paralysis, casts/splints
• Heart failure: Reduced cardiac output → venous congestion
• Venous obstruction: External compression (mass, pregnancy), venous insufficiency, varicose veins

2. Endothelial Injury (Vascular Wall Damage)

Mechanisms:

• Loss of normal anticoagulant endothelial surface (heparan sulfate, thrombomodulin)
• Exposure of subendothelial collagen → platelet adhesion and activation
• Endothelial activation → expression of tissue factor (TF), von Willebrand factor (vWF), P-selectin
• Inflammatory mediator release → leukocyte-platelet aggregation

Clinical scenarios:

• Direct trauma: Surgery, fractures, central venous catheters
• Indirect injury: Infection, hypoxia, inflammatory diseases (IBD, vasculitis)
• Chronic damage: Prior VTE (residual vein abnormalities), venous hypertension

3. Hypercoagulability (Blood Composition Changes)

Acquired hypercoagulable states:

Inherited hypercoagulable states:

• Loss-of-function mutations → Reduced natural anticoagulants:

  • "Antithrombin deficiency: Impaired thrombin and factor Xa inhibition"
  • "Protein C/S deficiency: Impaired inactivation of factors Va and VIIIa"

• Gain-of-function mutations → Enhanced procoagulant factors:

  • "Factor V Leiden (R506Q): Resistance to activated protein C (APC resistance)"
  • "Prothrombin G20210A: Elevated prothrombin levels (120-130% of normal)"

Thrombus Formation and Propagation

Phase 1: Initiation (Valve Pockets)

• Stasis in venous valve sinuses → local hypoxia
• Endothelial activation → leukocyte adhesion, microparticle release
• Tissue factor exposure → activation of extrinsic pathway
• Small platelet-fibrin nidus forms

Phase 2: Propagation (Extension)

• Thrombin generation activates factors V, VIII, XI (positive feedback)
• Fibrin mesh traps red blood cells → "red thrombus" characteristic of venous thrombosis
• Proximal and distal extension along vessel
• Critical point: Extends beyond valve pockets into main venous channels

Phase 3: Potential Outcomes

1. Resolution/Organization (weeks to months):

   • Endogenous fibrinolysis (plasmin activation)
   • Fibroblast invasion → scar tissue
   • Recanalization (partial or complete)
   • Residual valve damage → post-thrombotic syndrome risk

2. Embolization:

   • Thrombus detaches (especially with sudden mobilization after immobility)
   • Travels via IVC → right heart → pulmonary arteries
   • Proximal DVT (popliteal, femoral, iliac): 50% PE risk if untreated
   • Isolated calf/distal DVT: less than 5% PE risk; 15-30% propagate proximally if untreated

3. Persistent thrombosis:

   • Chronic occlusion → collateral formation
   • Chronic venous hypertension → PTS
   • Rarely: phlegmasia cerulea dolens (massive ileofemoral DVT → venous gangrene)

Pulmonary Embolism Pathophysiology

Hemodynamic Consequences:

The impact of PE depends on:

1. Size and location of emboli
2. Underlying cardiopulmonary reserve
3. Presence of neurohumoral mediators (serotonin, thromboxane)

Small to Moderate PE (Non-massive):

• Occlusion of less than 50% pulmonary vascular bed
• Minimal hemodynamic impact if normal cardiopulmonary reserve
• Compensatory mechanisms: Redistribution of flow, reflex tachycardia
• May cause: Pleuritic chest pain (pulmonary infarction), hemoptysis, pleural effusion

Submassive PE (Intermediate-risk):

• Occlusion 30-50% pulmonary vascular bed
• Right ventricular (RV) strain without systemic hypotension
• Pathophysiology:
  • Increased RV afterload → RV dilation and dysfunction
  • Decreased RV stroke volume → reduced LV preload → reduced cardiac output (may still maintain BP)
  • RV ischemia (increased wall tension, reduced coronary perfusion pressure)
  • "Elevated biomarkers: BNP/NT-proBNP (RV stretch), troponin (RV ischemia)"

Massive PE (High-risk):

• Occlusion > 50% pulmonary vascular bed OR saddle embolus
• Hemodynamic instability: SBP less than 90 mmHg or drop > 40 mmHg for > 15 minutes
• Pathophysiology:
  • Severe RV failure → RV dilation
  • Interventricular septal shift (D-shaped LV on echo)
  • Severely reduced LV preload → cardiogenic shock
  • RV ischemia/infarction → possible cardiac arrest
  • "Reflexes: Serotonin/thromboxane release → pulmonary vasoconstriction, bronchoconstriction"
• Mortality: 15-25% despite treatment [5]

Gas Exchange Abnormalities:

• V/Q mismatch: Perfusion defect with preserved ventilation → dead space, hypoxemia
• Intrapulmonary shunt: Atelectasis distal to occluded vessels
• Low mixed venous O2: Reduced cardiac output
• Result: Hypoxemia (present in 85% of PE, but PaO2 can be normal in 15%)

---

4. Clinical Presentation

Deep Vein Thrombosis (DVT)

Classic Presentation (Present in ~50% of DVT):

• Unilateral leg swelling: Most sensitive sign (calf circumference difference > 3 cm)
• Pain/tenderness: Along deep venous distribution (calf, popliteal fossa, adductor canal)
• Warmth and erythema: Overlying affected vein
• Pitting edema: Extends from foot to affected level

Atypical Presentations:

• Asymptomatic DVT: 50% of DVT are asymptomatic, discovered during PE workup
• Bilateral symptoms: Suggests IVC thrombosis or bilateral DVT (rare; consider alternative diagnosis)
• Upper extremity DVT (UEDVT): 4-10% of DVT
  • "Primary (Paget-Schroetter syndrome): Effort-induced, in athletes/heavy laborers (thoracic outlet compression)"
  • "Secondary: Central venous catheters (50% of UEDVT), pacemaker leads, malignancy"
  • "PE risk from UEDVT: 6-12% (lower than lower extremity DVT)"

DVT by Location:

Special Scenarios:

Phlegmasia Cerulea Dolens (Venous Gangrene):

• Massive ileofemoral DVT → complete venous occlusion
• Clinical: Severe leg pain, marked swelling, cyanosis, venous gangrene
• Compartment syndrome risk, arterial insufficiency (compromised arterial inflow)
• Emergency: Requires catheter-directed thrombolysis, thrombectomy, or surgical fasciotomy

Superficial Thrombophlebitis:

• Palpable cord (thrombosed superficial vein), erythema, tenderness
• Usually benign, but 6-40% associated with DVT if near sapheno-femoral junction
• Requires ultrasound to exclude DVT extension

Pulmonary Embolism (PE)

Classic Triad (Present in less than 20% of PE):

• Dyspnea
• Pleuritic chest pain
• Hemoptysis

Most Common Symptoms:

Most Common Signs:

PE Severity Classification:

Clinical Prediction Rules:

Simplified Pulmonary Embolism Severity Index (sPESI): [8]

• 1 point each for:
  • Age > 80 years
  • Cancer (active)
  • Chronic cardiopulmonary disease (HF or COPD)
  • Heart rate ≥110 bpm
  • Systolic BP less than 100 mmHg
  • Arterial oxygen saturation less than 90%
• Score = 0 → Low risk (30-day mortality less than 1%) → Candidate for outpatient management
• Score ≥1 → Higher risk → Hospitalize

Atypical Presentations:

Silent PE:

• Asymptomatic PE found incidentally (e.g., on staging CT for cancer)
• Frequency: 40-60% of PE may be asymptomatic
• Management: Same as symptomatic PE (anticoagulation required)

Recurrent PE:

• New or worsening symptoms on anticoagulation
• Differential: Inadequate anticoagulation, adherence issues, resistance (rare), alternative diagnosis
• Requires reassessment of anticoagulation intensity/agent

Red Flags

[!CAUTION] Red Flags — Immediate Escalation Required:

Massive PE Indicators:

• Hemodynamic instability: SBP less than 90 mmHg, sustained hypotension, or vasopressor requirement
• Cardiac arrest or peri-arrest rhythms
• Severe hypoxemia: SpO2 less than 90% despite supplemental oxygen
• Syncope with suspected PE (suggests high clot burden or intermittent RV outflow obstruction)
• Signs of RV failure: Elevated JVP, tricuspid regurgitation murmur, RV heave
• → Action: Activate PE response team, consider thrombolysis, ICU transfer

DVT Complications:

• Phlegmasia cerulea dolens: Severely swollen, blue, painful leg → risk of venous gangrene
• Compartment syndrome: Severe pain, tense compartments, neurological deficit
• → Action: Urgent vascular surgery consult, consider catheter-directed thrombolysis

Paradoxical Embolism:

• PE + arterial thromboembolism (stroke, limb ischemia) → suggests intracardiac shunt (PFO)
• → Action: Echocardiography with bubble study, neurology/vascular consult

---

5. Diagnosis & Investigations

Diagnostic Strategy: Sequential Probability-Based Approach

VTE diagnosis requires objective testing. Clinical gestalt alone is unreliable (sensitivity ~50% for DVT, ~40% for PE). Modern diagnosis integrates pretest probability assessment, D-dimer testing (when appropriate), and definitive imaging. [2]

Validated Approach:

1. Assess pretest (clinical) probability using validated score (Wells)
2. D-dimer testing if non-high probability (to exclude VTE without imaging)
3. Definitive imaging if high probability or D-dimer positive

Pretest Probability Assessment

Wells Score for DVT: [2,17]

Interpretation:

• Wells ≤0: Low probability (5% prevalence)
• Wells 1-2: Moderate probability (17% prevalence)
• Wells ≥3: High probability (53% prevalence)

Dichotomized (two-level) Wells:

• Unlikely (Wells ≤1): Proceed to D-dimer
• Likely (Wells ≥2): Proceed directly to imaging

Wells Score for PE: [2,17]

Interpretation:

• Wells ≤4: Low/moderate probability (PE unlikely)
• Wells > 4: High probability (PE likely)

Alternative: Revised Geneva Score: Similar performance to Wells; uses purely clinical variables (no subjective "alternative diagnosis" component).

Clinical Pearl: Both Wells and Geneva scores perform similarly. Choose one and use consistently. The "alternative diagnosis" component in Wells is subjective but often clinically useful.

D-Dimer Testing

What is D-Dimer?

• Fibrin degradation product (cross-linked fibrin breakdown)
• Elevated in thrombosis, but also: infection, inflammation, malignancy, pregnancy, surgery, trauma, advanced age

Test Characteristics:

• Sensitivity: 95-98% (high; rarely negative in VTE)
• Specificity: 40-60% (low; many false positives)
• Negative Predictive Value: > 99% when combined with non-high pretest probability

Clinical Use: [2]

• ✅ Use to EXCLUDE VTE in patients with low or moderate (non-high) pretest probability
• ❌ Do NOT use in high pretest probability (proceed directly to imaging)
• ❌ Do NOT use as a "rule-in" test (positive D-dimer does NOT diagnose VTE; requires imaging)

Age-Adjusted D-Dimer Threshold: [18]

• Standard cutoff: 500 ng/mL (or 0.5 mg/L FEU)
• Age-adjusted cutoff (for age > 50 years): Age × 10 ng/mL (or Age × 0.01 mg/L FEU)
  • "Example: 70-year-old patient → cutoff = 700 ng/mL"
• Rationale: D-dimer increases with age; age-adjusted cutoff increases specificity (reduces false positives) without sacrificing safety
• Impact: Increases proportion of patients > 50 years with VTE excluded (reduces unnecessary imaging by ~30%)

When D-Dimer is NOT useful:

• Hospitalized patients (high false positive rate)
• Postoperative patients
• Pregnancy (D-dimer physiologically elevated)
• Known malignancy
• In these scenarios: Proceed directly to imaging if VTE suspected

Validated Strategy (YEARS Algorithm): [19]

• Combines simplified Wells items with D-dimer
• If 0 YEARS items + D-dimer less than 1000 ng/mL: VTE excluded
• If ≥1 YEARS item + D-dimer less than 500 ng/mL: VTE excluded
• Otherwise: Imaging required

Imaging for DVT

First-Line: Compression Ultrasonography (CUS) [20]

Technique:

• Compression test: Failure to fully compress vein with transducer pressure = thrombosis
• Two-point CUS: Common femoral vein + popliteal vein only (proximal DVT)
• Whole-leg CUS: Includes calf veins (distal DVT)

Diagnostic Criteria for DVT:

• Direct sign: Non-compressible vein (sensitivity 95%, specificity 98% for proximal DVT)
• Supportive findings: Absent or reduced color Doppler flow, dilated vein, visible echogenic thrombus, absent phasicity with respiration

Sensitivity/Specificity:

• Proximal DVT: Sensitivity 95%, specificity 98%
• Distal/calf DVT: Sensitivity 70-80% (operator-dependent)
• Recurrent DVT: Reduced accuracy (chronic vein changes may persist)

Limitations:

• Poor visualization: Obesity, edema, calf veins, IVC, iliac veins, pelvic veins
• Operator-dependent
• Asymptomatic DVT: Lower sensitivity

If Initial CUS Negative but Clinical Suspicion Persists:

• Repeat CUS in 5-7 days (detects propagating distal DVT)
• OR whole-leg ultrasound immediately
• OR consider alternative imaging (MR venography, CT venography)

Alternative Imaging:

Imaging for PE

First-Line: CT Pulmonary Angiography (CTPA) [21]

Technique:

• IV contrast-enhanced CT during peak pulmonary arterial opacification
• Multidetector CT (MDCT): Thin slices (1-1.25 mm) → subsegmental vessel visualization

Diagnostic Criteria:

• Positive: Intraluminal filling defect surrounded by contrast (complete or partial occlusion)
• Location: Main, lobar, segmental, or subsegmental pulmonary arteries

Sensitivity/Specificity:

• Segmental or larger PE: Sensitivity 95-100%, specificity 95-98%
• Isolated subsegmental PE: Sensitivity 75-85% (some missed; clinical significance debated)

Advantages:

• High accuracy, fast, widely available
• Assesses alternative diagnoses (pneumonia, aortic dissection, pneumothorax)
• Evaluates RV:LV ratio (RV dysfunction if > 1.0)

Disadvantages:

• Radiation (effective dose ~10-15 mSv; breast tissue exposure)
• Contrast (renal impairment, allergy)
• Overdiagnosis: Subsegmental PE may be clinically insignificant

Contraindications/Caution:

• Severe renal impairment (eGFR less than 30 mL/min): Consider V/Q scan
• Contrast allergy: Premedicate or use V/Q scan
• Pregnancy: V/Q scan preferred (less fetal radiation)

Alternative Imaging:

Ventilation-Perfusion (V/Q) Scintigraphy:

Indications:

• Contraindication to CTPA (renal failure, contrast allergy)
• Pregnancy (V/Q scan lower fetal radiation than CTPA)
• Young women (to reduce breast radiation)

Technique:

• Perfusion (Q) scan: IV technetium-99m macroaggregated albumin → detects perfusion defects
• Ventilation (V) scan: Inhaled gas or aerosol → detects ventilation

Interpretation (PIOPED II Criteria):

• Normal: No perfusion defects → PE excluded (NPV > 95%)
• High probability: ≥2 large mismatched segmental perfusion defects → PE confirmed (PPV > 90%)
• Intermediate/Low probability: Non-diagnostic → requires further testing (CTPA or clinical algorithm)
• Non-diagnostic rate: 30-50% (limitation)

Sensitivity/Specificity:

• Comparable to CTPA for segmental or larger PE
• Better for subsegmental PE (CTPA may overcall subsegmental PE)

Pulmonary Angiography (Gold Standard, Rarely Used):

• Invasive, requires catheterization
• Reserved for cases where CTPA/V/Q non-diagnostic and high clinical suspicion
• May perform catheter-directed intervention if PE confirmed

Investigations for Risk Stratification

For Pulmonary Embolism:

1. Biomarkers:

• Role: Identify normotensive patients with RV dysfunction (submassive PE) who may benefit from closer monitoring or escalation of care

2. Echocardiography:

Findings in PE:

• RV dilation (RV:LV ratio > 0.9)
• RV hypokinesis (McConnell sign: RV free wall hypokinesis with apical sparing)
• Interventricular septal flattening/paradoxical motion (D-shaped LV)
• Tricuspid regurgitation with elevated RVSP
• Rarely: Visualized thrombus in right heart chambers ("thrombus in transit" → very high risk)

Clinical Use:

• Risk stratification of normotensive PE (RV dysfunction = submassive PE)
• Bedside assessment in unstable patients (cannot wait for CTPA)
• Rarely diagnostic alone (sensitivity 50-60% for PE; mainly a risk stratification tool)

3. Clinical Prediction Score:

Simplified PESI (sPESI): See above [8]

• Score 0 → Low risk → Outpatient candidate
• Score ≥1 → Higher risk → Hospitalize

Integrated Risk Stratification Algorithm (ESC 2019 Guidelines): [22]

Investigations for Thrombophilia

ASH 2023 Guidelines on Thrombophilia Testing: [10]

Recommended Testing Scenarios (Conditional recommendations):

1. Unprovoked VTE in young patient (less than 50 years) with strong family history of VTE → Test for inherited thrombophilia (may influence family counseling, duration of therapy in severe deficiencies)
2. Recurrent VTE (unprovoked) → Consider testing
3. Unusual site thrombosis (cerebral venous sinus, splanchnic, portal) → Test for myeloproliferative neoplasms (JAK2, CALR, MPL mutations), paroxysmal nocturnal hemoglobinuria (PNH), antiphospholipid syndrome
4. Suspected antiphospholipid syndrome → Test (lupus anticoagulant, anticardiolipin antibodies, anti-β2-glycoprotein I antibodies)

NOT Recommended:

• ❌ Routine testing after first provoked VTE
• ❌ Testing the general population before oral contraceptives
• ❌ Testing asymptomatic family members (low yield, causes anxiety)

Thrombophilia Panel (if testing indicated):

Timing of Testing:

• Ideally: After completing anticoagulation (or before starting, if suspected)
• Acceptable: On DOAC if using chromogenic/anti-Xa-based assays (laboratory-specific)
• Not during acute VTE: Protein C, protein S, antithrombin may be consumed (false low levels)

---

6. Management

General Principles

Goals of VTE Management:

1. Prevent PE (from DVT) or recurrent PE
2. Prevent thrombus extension
3. Reduce acute symptoms
4. Prevent long-term complications (PTS, CTEPH)
5. Minimize bleeding risk from anticoagulation

Key Decisions:

1. Initial therapy: Which anticoagulant? (DOAC vs. warfarin vs. LMWH alone)
2. Setting of care: Outpatient vs. inpatient?
3. Duration: 3 months? 6 months? Indefinite?
4. Advanced therapy: Thrombolysis? Catheter-directed intervention? IVC filter?

Acute Management of DVT

Initial Anticoagulation (Start Immediately if Diagnosis Confirmed or Highly Suspected):

First-Line: Direct Oral Anticoagulants (DOACs) [3,4,23]

Preferred over warfarin for most patients (non-inferior efficacy, lower major bleeding, no monitoring required).

Network Meta-Analysis (Comparison of DOACs): [24]

• Efficacy (VTE recurrence): All DOACs similar to each other and to warfarin
• Safety (major bleeding): Apixaban < Edoxaban ≈ Dabigatran ≈ Rivaroxaban < Warfarin
• Practical: Apixaban and rivaroxaban preferred (no parenteral lead-in)

Alternative: Warfarin (Vitamin K Antagonist)

Indications for Warfarin over DOAC:

• Antiphospholipid syndrome (DOACs inferior; warfarin preferred) [16]
• Severe renal impairment (CrCl less than 15-30 mL/min; depends on DOAC)
• Mechanical heart valves (DOACs contraindicated)
• Cost/insurance restrictions

Low Molecular Weight Heparin (LMWH) Monotherapy:

Indications for LMWH Monotherapy:

• Cancer-associated VTE (LMWH superior to warfarin; DOAC alternative if no high-risk features) [12]
• Pregnancy (warfarin/DOACs contraindicated)
• Bridge to warfarin (if warfarin chosen)
• Severe renal impairment precluding DOAC (use UFH if CrCl less than 30)

Unfractionated Heparin (UFH):

Indications:

• Severe renal impairment (CrCl less than 30 mL/min; UFH is not renally cleared)
• High bleeding risk (short half-life; reversible with protamine)
• Peri-procedural (can rapidly stop/reverse)
• Hospitalized patients requiring IV therapy

Fondaparinux (Synthetic Factor Xa Inhibitor):

• Dosing: less than 50 kg: 5 mg SC daily; 50-100 kg: 7.5 mg daily; > 100 kg: 10 mg daily
• No monitoring required
• Avoid if CrCl less than 30
• Used as bridge to warfarin or in HIT (heparin-induced thrombocytopenia)

DVT-Specific Considerations:

Isolated Distal (Calf) DVT:

• Symptomatic + risk factors for propagation (extensive clot, no reversible trigger, active cancer, prior VTE, inpatient) → Anticoagulate (same as proximal DVT)
• Asymptomatic or limited clot → Option to serial ultrasound (repeat in 1 week) and anticoagulate if propagates
• Duration if treated: 3 months

Proximal DVT (Popliteal or Above):

• Always anticoagulate (high PE risk)
• Duration: See below (depends on provoked vs. unprovoked)

Upper Extremity DVT:

• Catheter-associated: Anticoagulate if symptomatic or catheter will remain; consider removing catheter
• Primary (Paget-Schroetter): Anticoagulate + consider catheter-directed thrombolysis + surgical thoracic outlet decompression (in selected young patients)

Acute Management of Pulmonary Embolism

Risk Stratification First (Determines treatment intensity and setting):

Massive (High-Risk) PE:

• Hemodynamic instability (SBP less than 90 mmHg, vasopressors, cardiac arrest)
• Management:
  • "Resuscitation: IV fluids (cautious; 500 mL bolus; avoid overload → worsens RV failure), vasopressors (norepinephrine preferred)"
  • "Anticoagulation: Start immediately (UFH preferred; aPTT 1.5-2.5×; easier to manage peri-thrombolysis)"
  • "Reperfusion Therapy:"

Systemic Thrombolysis (First-Line for Massive PE): [5,25]

Contraindications to Thrombolysis:

• Absolute: Active bleeding, recent intracranial/intraspinal surgery or trauma (less than 3 months), intracranial neoplasm/AVM, ischemic stroke less than 3 months
• Relative: Major surgery less than 10 days, GI bleeding less than 3 months, severe uncontrolled HTN (SBP > 180), recent invasive procedure, pregnancy, bleeding diathesis

Major Bleeding Risk: 10-15% (intracranial hemorrhage: 1-3%)

Alternative to Thrombolysis: Catheter-Directed Therapy

• Catheter-directed thrombolysis, fragmentation, or aspiration thrombectomy
• Indications: Contraindication to systemic lysis, failed systemic lysis, or institution with expertise
• Requires interventional radiology/cardiology resources

Surgical Embolectomy:

• Rarely performed; for patients who fail or have contraindication to thrombolysis
• Requires cardiothoracic surgery, cardiopulmonary bypass

ECMO:

• For refractory cardiac arrest or severe shock
• Bridge to reperfusion therapy or recovery

Submassive (Intermediate-Risk) PE:

• Normotensive but RV dysfunction + elevated troponin
• Management:
  • Hospitalize (monitor for decompensation)
  • "Anticoagulation: DOAC or LMWH/warfarin (same as low-risk)"
  • "Thrombolysis: ❓ Controversial"
    • PEITHO Trial [26]: Thrombolysis reduced hemodynamic decompensation but increased major bleeding (including ICH)
    • Current Approach: Individualized decision (consider if high-risk features: extensive clot burden, worsening RV function, clinical deterioration, low bleeding risk)
    • Reduced-dose thrombolysis ("half-dose" or "safe-dose" lysis): Under investigation; may reduce bleeding

Low-Risk PE:

• Normotensive, no RV dysfunction, PESI class I-II or sPESI = 0
• Management:
  • "Anticoagulation: DOAC preferred (same regimens as DVT)"
  • "Setting: Outpatient management or early discharge (less than 24-48 hours) if:"
    • Reliable follow-up
    • No significant comorbidities
    • Adequate social support
    • No high bleeding risk
  • "HESTIA Criteria (Exclusion criteria for outpatient PE): [27]"
    • Hemodynamic instability
    • Thrombolysis or embolectomy needed
    • Active bleeding or high bleeding risk
    • Supplemental oxygen required to maintain SpO2 > 90%
    • PE diagnosed during anticoagulation
    • Severe pain requiring IV analgesia > 24 hours
    • Medical or social reason for hospitalization > 24 hours
    • CrCl less than 30 mL/min
    • Severe liver disease
    • Pregnancy
    • Documented thrombocytopenia

Duration of Anticoagulation: The Critical Decision

Duration depends primarily on VTE classification (provoked vs. unprovoked) and bleeding risk. [6,9]

Provoked VTE:

Unprovoked VTE:

Key Factors in Extended Therapy Decision:

Favor Indefinite Anticoagulation:

• Male sex (10%/year recurrence vs. 5%/year in women) [6]
• Recurrent VTE (especially if unprovoked)
• Proximal DVT or PE (vs. distal DVT)
• Elevated D-dimer 1 month after stopping anticoagulation (predictor of recurrence)
• Low bleeding risk (HAS-BLED score less than 3, age less than 65, no prior bleeding)
• Patient preference (values stroke/recurrence prevention over bleeding risk)

Favor Stopping at 3-6 Months:

• Female sex with first unprovoked VTE
• High bleeding risk (HAS-BLED ≥3, prior major bleeding, age > 75, anemia, renal/liver impairment, falls)
• Distal DVT only
• Patient preference (values avoiding bleeding/anticoagulation burden)

Reduced-Dose Extended Anticoagulation:

• Rivaroxaban 10 mg daily (vs. 20 mg): EINSTEIN CHOICE trial → reduced recurrence vs. aspirin, similar bleeding to aspirin [28]
• Apixaban 2.5 mg BID (vs. 5 mg BID): AMPLIFY EXTENSION trial → reduced recurrence vs. placebo, no increase in major bleeding [29]
• Use: After completing 6-12 months of therapeutic anticoagulation, may transition to reduced dose for extended prophylaxis (lower bleeding risk)

Aspirin for Extended VTE Prevention:

• ASPIRE, WARFASA trials: Aspirin 100 mg daily reduces recurrence by ~30% vs. placebo (but less effective than anticoagulation)
• Use: If patient declines or has contraindication to anticoagulation

Special Populations

Cancer-Associated Thrombosis (CAT): [12]

• Incidence: 4-7× higher VTE risk; leading cause of death in cancer patients (after cancer itself)
• High-risk cancers: Pancreatic, brain, gastric, lung, ovarian, hematologic malignancies
• Initial therapy:
  • "LMWH monotherapy (preferred historically): Dalteparin 200 units/kg × 1 month, then 150 units/kg daily"
  • "DOACs (emerging as alternative): [30]"
    • Edoxaban (HOKUSAI-VTE Cancer): Non-inferior to dalteparin; ↑ major bleeding (GI, GU)
    • Rivaroxaban (SELECT-D): Effective; ↑ bleeding in GI/GU malignancies
    • Apixaban (CARAVAGGIO): Non-inferior to dalteparin; similar bleeding
    • Recommendation: DOAC acceptable if no high bleeding risk (no GI/GU tumor, no thrombocytopenia, no recent bleeding)
• Duration: Indefinite (while cancer active or on chemotherapy; minimum 6 months)
• Recurrent VTE on anticoagulation: Increase LMWH dose (by 25-33%), switch to DOAC, or add IVC filter (controversial)

Pregnancy-Associated VTE:

• Incidence: 1-2 per 1,000 pregnancies (4-5× general population); highest risk: early postpartum
• Anticoagulation:
  • LMWH throughout pregnancy (warfarin/DOACs teratogenic; cross placenta)
  • Enoxaparin 1 mg/kg SC q12h (adjust for weight gain; monitor anti-Xa if extremes of weight, renal impairment)
  • Switch to UFH at 36 weeks (if planned epidural/spinal anesthesia; shorter half-life)
  • "Postpartum: Continue LMWH or switch to warfarin (safe in breastfeeding) × minimum 6 weeks postpartum (total duration pregnancy + postpartum ≥6 months)"

Renal Impairment:

Adjunctive Therapies

Compression Stockings for DVT:

• Historical use: Graduated compression stockings (30-40 mmHg) to prevent post-thrombotic syndrome (PTS)
• SOX Trial [31]: NO benefit of compression stockings for PTS prevention
• Current recommendation: NOT routinely recommended for PTS prevention; may use for symptom relief during acute DVT

Ambulation:

• Early mobilization (after starting anticoagulation) is safe and encouraged
• Does NOT increase PE risk (traditional bedrest advice is outdated)

Inferior Vena Cava (IVC) Filters: [32]

Indications:

• Absolute: Acute VTE with contraindication to anticoagulation (active bleeding, recent surgery with high bleeding risk)
• Relative/Controversial:
  • Recurrent VTE despite therapeutic anticoagulation (rare; first optimize anticoagulation)
  • Free-floating IVC/iliofemoral thrombus (no clear benefit)
  • Massive PE treated with thrombolysis (no clear benefit)
  • "Prophylactic (trauma, surgery): NOT recommended (no mortality benefit, ↑ DVT risk)"

Types:

• Retrievable: Preferred (remove when anticoagulation resumed); high rates of non-retrieval in practice (~50%)
• Permanent: Only if lifelong contraindication to anticoagulation

Complications:

• Filter thrombosis (5-10%)
• IVC occlusion (2-10%)
• Filter migration, fracture, perforation (rare)
• Increased DVT risk: 20-30% long-term (PREPIC trial) [33]

Recommendation: Use sparingly; retrievable filter preferred; remove as soon as anticoagulation resumed; anticoagulate if possible even with filter in place

---

7. Complications & Prognosis

Acute Complications (Days to Weeks)

Pulmonary Embolism (from DVT):

• Incidence: 50% of untreated proximal DVT → PE (many asymptomatic)
• Prevention: Early anticoagulation
• Mortality: Massive PE 15-25% despite treatment

Recurrent VTE on Anticoagulation:

• Incidence: 1-3% on therapeutic anticoagulation
• Causes: Non-adherence (most common), inadequate dosing, resistance (rare), cancer progression
• Management: Check adherence, check anti-Xa or INR (if applicable), consider dose escalation or switch agent, exclude cancer progression

Bleeding on Anticoagulation:

• Major bleeding: 1-3% per year on therapeutic anticoagulation
• Fatal bleeding: 0.2-0.5% per year
• Risk factors: Age > 75, prior bleeding, anemia, renal impairment, concomitant antiplatelet agents, falls
• Management: See reversal strategies below

Anticoagulation Reversal:

Chronic Complications (Months to Years)

Post-Thrombotic Syndrome (PTS): [34]

• Definition: Chronic venous insufficiency following DVT (pain, swelling, skin changes, ulceration)
• Incidence: 20-50% after proximal DVT (despite anticoagulation)
• Pathophysiology: Residual venous obstruction + valvular incompetence → chronic venous hypertension
• Risk factors: Proximal/extensive DVT, recurrent ipsilateral DVT, obesity, older age, inadequate anticoagulation
• Clinical features:
  • "Mild-moderate: Leg heaviness, aching, swelling (worse with prolonged standing), skin hyperpigmentation"
  • "Severe: Lipodermatosclerosis, venous ulceration"
• Diagnosis: Villalta Score (symptom + sign scale; score ≥5 = PTS; ≥15 = severe PTS)
• Prevention:
  • ❌ Compression stockings: NO benefit (SOX trial) [31]
  • ✅ Adequate anticoagulation (prevents recurrence → PTS)
  • ❓ Catheter-directed thrombolysis for extensive ileofemoral DVT (ATTRACT trial: no benefit for PTS overall; possible benefit in iliofemoral DVT subgroup) [35]
• Treatment:
  • Leg elevation, weight loss, exercise
  • Compression stockings (20-30 mmHg) for symptom relief
  • "Venoactive drugs (diosmin, micronized purified flavonoid fraction): modest benefit"
  • Venous stenting for iliac vein obstruction (selected patients)

Chronic Thromboembolic Pulmonary Hypertension (CTEPH): [36]

• Definition: Pulmonary hypertension (mPAP ≥25 mmHg) due to chronic thromboembolic obstruction
• Incidence: 2-4% after acute PE
• Pathophysiology: Incomplete thrombus resolution → organized fibrotic obstruction → pulmonary vascular remodeling → pulmonary hypertension
• Risk factors: Large PE, recurrent PE, idiopathic/unprovoked PE, younger age
• Clinical features: Progressive dyspnea on exertion (often delayed months to years after PE), fatigue, syncope (late)
• Diagnosis:
  • "Screening: Echocardiography (elevated RVSP); consider in all patients 3-6 months post-PE if persistent symptoms"
  • "Confirmation: Right heart catheterization (gold standard for PH); V/Q scan (shows perfusion defects; more sensitive than CTPA)"
  • "CTPA: Shows chronic thromboembolic changes (webs, bands, mural thrombi)"
• Treatment:
  • "Pulmonary endarterectomy (PEA): Curative if surgically accessible disease (proximal)"
  • "Balloon pulmonary angioplasty (BPA): For distal/inoperable disease"
  • "Medical therapy: Riociguat (pulmonary vasodilator) if inoperable/residual PH"
  • Lifelong anticoagulation

Prognosis

Mortality:

• Untreated DVT: less than 1% (mortality from PE)
• Untreated PE: 25-30%
• Treated PE:
  • "Low-risk PE: less than 1%"
  • "Submassive PE: 3-15%"
  • "Massive PE: 15-25%"
• Long-term: Excess mortality in first year (due to underlying conditions: cancer, immobility)

Recurrence:

• See duration section above
• Overall: 30% at 10 years (unprovoked VTE off anticoagulation)
• On indefinite anticoagulation: 1-2% per year

Quality of Life:

• Most patients recover fully with appropriate anticoagulation
• PTS: Significantly impairs QoL (20-50% of DVT patients)
• CTEPH: Severe disability if untreated; improved with PEA
• Anticoagulation burden: Bleeding risk, dietary restrictions (warfarin), cost, monitoring

---

8. Prevention (VTE Prophylaxis)

High-Risk Scenarios Requiring Pharmacological Prophylaxis:

Surgical Patients: [37]

• Orthopedic surgery (hip/knee replacement, hip fracture): LMWH (enoxaparin 40 mg SC daily or 30 mg SC q12h) × 10-35 days OR rivaroxaban 10 mg daily × 10-35 days OR apixaban 2.5 mg BID × 10-35 days
• Major general surgery (cancer, abdominal, pelvic): LMWH (enoxaparin 40 mg SC daily) starting preoperatively or 12 hours postoperatively × 7-10 days (extended to 28 days for cancer surgery)

Medical Inpatients: [38]

• Acute medical illness with immobility + risk factors (age > 75, cancer, prior VTE, HF, respiratory failure): LMWH (enoxaparin 40 mg SC daily) or fondaparinux (2.5 mg SC daily) or UFH (5,000 units SC q8-12h) × duration of hospitalization
• Bleeding risk: Use mechanical prophylaxis (graduated compression stockings, intermittent pneumatic compression) if contraindication to pharmacological prophylaxis

NOT Indicated:

• Routine prophylaxis in general outpatient population
• Long-haul travel (unless multiple risk factors; consider compression stockings, hydration, mobilization)

---

9. Evidence & Guidelines

Key International Guidelines

1. American College of Chest Physicians (CHEST) Guidelines (2021): [9,23]

• Comprehensive VTE diagnosis and management
• Key recommendations:
  • Pretest probability + D-dimer for VTE exclusion
  • DOACs preferred over warfarin for most patients
  • "Provoked VTE: 3 months; unprovoked VTE: consider indefinite if low bleeding risk"
  • Thrombolysis for massive PE

2. European Society of Cardiology (ESC) Guidelines (2019): [22]

• PE-focused; integrated risk stratification
• Key recommendations:
  • PESI/sPESI + biomarkers + imaging for risk stratification
  • Outpatient management for low-risk PE (PESI I-II or sPESI 0)
  • Individualized thrombolysis decision for intermediate-risk PE

3. NICE Guidelines (UK) (2020): [39]

• VTE diagnosis, management, and thrombophilia testing
• Key recommendations:
  • Wells score + age-adjusted D-dimer
  • DOACs first-line (apixaban or rivaroxaban)
  • Limited role for thrombophilia testing

4. American Society of Hematology (ASH) Guidelines (2023): [10]

• Thrombophilia testing in VTE
• Key recommendations:
  • Against routine thrombophilia testing after provoked VTE
  • Against population screening before oral contraceptives
  • Conditional recommendations for testing in selected scenarios (unprovoked VTE in young with family history, unusual site thrombosis)

Landmark Trials

Diagnostic Trials:

1. Wells Validation Studies (2003-2006): [17]

• Validated Wells score for DVT and PE
• Established pretest probability + D-dimer strategy
• Impact: Standard diagnostic algorithm worldwide

2. YEARS Study (2017): [19]

• Simplified diagnostic algorithm for PE (YEARS criteria + D-dimer)
• Finding: Reduced imaging by 14% without missing PE
• Impact: Alternative to Wells + D-dimer

Treatment Trials (DOACs vs. Warfarin):

3. EINSTEIN-DVT/PE Trials (2010, 2012): [3]

• Intervention: Rivaroxaban vs. enoxaparin/warfarin
• Finding: Non-inferior efficacy, lower major bleeding
• Impact: First DOAC approved for VTE

4. AMPLIFY Trial (2013): [4]

• Intervention: Apixaban vs. enoxaparin/warfarin
• Finding: Non-inferior efficacy, significantly lower major bleeding (RR 0.31)
• Impact: Established apixaban as lowest-bleeding DOAC

5. HOKUSAI-VTE Trial (2013):

• Intervention: Edoxaban (after LMWH lead-in) vs. warfarin
• Finding: Non-inferior efficacy, lower major bleeding
• Impact: Approved edoxaban for VTE (requires lead-in)

6. RE-COVER Trials (2009, 2014):

• Intervention: Dabigatran (after LMWH lead-in) vs. warfarin
• Finding: Non-inferior efficacy, similar bleeding
• Impact: Approved dabigatran (requires lead-in)

Duration Trials:

7. AMPLIFY EXTENSION (2013): [29]

• Intervention: Apixaban 2.5 mg BID or 5 mg BID vs. placebo (extended prophylaxis after 6-12 months)
• Finding: Both doses reduced recurrence vs. placebo; no increase in major bleeding with 2.5 mg dose
• Impact: Established reduced-dose apixaban for extended prophylaxis

8. EINSTEIN CHOICE (2017): [28]

• Intervention: Rivaroxaban 20 mg vs. 10 mg vs. aspirin (extended prophylaxis)
• Finding: Both rivaroxaban doses superior to aspirin; 10 mg had similar bleeding to aspirin
• Impact: Established reduced-dose rivaroxaban (10 mg) for extended prophylaxis

Thrombolysis Trials:

9. PEITHO Trial (2014): [26]

• Intervention: Thrombolysis (tenecteplase) vs. heparin in normotensive PE with RV dysfunction
• Finding: Reduced hemodynamic decompensation (1.6% vs. 5%) but increased major bleeding (6.3% vs. 1.2%) and stroke (2.4% vs. 0.2%)
• Impact: Thrombolysis for intermediate-risk PE remains controversial; individualize decision

Cancer-Associated VTE:

10. HOKUSAI-VTE Cancer (2018):

• Intervention: Edoxaban vs. dalteparin in cancer-associated VTE
• Finding: Non-inferior efficacy; higher bleeding (GI cancers)
• Impact: DOAC option for CAT (avoid in high bleeding risk)

11. CARAVAGGIO Trial (2020): [30]

• Intervention: Apixaban vs. dalteparin in cancer-associated VTE
• Finding: Non-inferior efficacy; similar bleeding (including in GI cancers)
• Impact: Apixaban preferred DOAC for CAT

PTS Prevention:

12. SOX Trial (2014): [31]

• Intervention: Compression stockings vs. placebo for PTS prevention after DVT
• Finding: NO benefit (30% PTS in both groups)
• Impact: Compression stockings NOT recommended for PTS prevention

13. ATTRACT Trial (2017): [35]

• Intervention: Catheter-directed thrombolysis vs. anticoagulation alone for proximal DVT
• Finding: No reduction in PTS overall; possible benefit in iliofemoral DVT subgroup
• Impact: Routine CDT not recommended; consider in selected patients (young, iliofemoral DVT, low bleeding risk)

---

10. Exam Viva Scenarios & Clinical Reasoning

Viva Scenario 1: Young Woman with Leg Swelling on Oral Contraceptive

Scenario: A 28-year-old woman presents to the Emergency Department with a 2-day history of left leg swelling and pain. She takes the combined oral contraceptive pill (ethinylestradiol/levonorgestrel). She denies recent trauma, surgery, or prolonged immobility. She is otherwise well.

On Examination:

• Vitals: HR 88 bpm, BP 125/78 mmHg, RR 14/min, SpO2 98% on air, Temp 37.1°C
• Left calf circumference: 39 cm (vs. right: 33 cm; difference: 6 cm)
• Left calf tender to palpation along deep venous distribution
• Mild pitting edema to mid-shin
• No chest pain, dyspnea, or hemoptysis

Viva Questions & Model Answers:

Q1: What is your differential diagnosis?

A1:

• Most likely: Deep vein thrombosis (DVT)
  • Unilateral leg swelling + pain + risk factor (COC)
  • Calf circumference difference > 3 cm
  • Tender along deep venous distribution
• Alternative diagnoses:
  • Ruptured Baker's cyst (mimics DVT; may have history of knee pain/arthritis)
  • Cellulitis (usually erythema, warmth, fever)
  • Superficial thrombophlebitis (palpable cord, more superficial)
  • Muscle strain or hematoma (history of trauma)
  • Lymphedema (gradual onset, bilateral)

Q2: How would you risk-stratify this patient for DVT?

A2: Wells Score for DVT (calculate points):

• Active cancer: No = 0
• Paralysis/paresis/recent immobilization: No = 0
• Recently bedridden > 3 days or major surgery less than 12 weeks: No = 0
• Localized tenderness along deep veins: Yes = +1
• Entire leg swollen: No = 0 (calf only)
• Calf swelling > 3 cm vs. asymptomatic leg: Yes = +1
• Pitting edema (greater in symptomatic leg): Yes = +1
• Collateral superficial veins (non-varicose): No = 0
• Previously documented DVT: No = 0
• Alternative diagnosis at least as likely: No = 0

Total Wells Score: 3 → High probability (53% prevalence)

Q3: What investigations would you order?

A3: Given high Wells score (≥2 = "DVT likely"):

• Proceed directly to compression ultrasonography (do NOT do D-dimer; positive D-dimer does not confirm DVT, and DVT cannot be excluded with negative D-dimer in high-probability patients)

Additional baseline tests:

• Full blood count, renal function, coagulation screen (baseline before anticoagulation)

Q4: The ultrasound shows non-compressible left popliteal vein with visible echogenic thrombus. How would you manage this patient?

A4: Diagnosis confirmed: Proximal DVT (popliteal vein)

Immediate Management:

1. Start anticoagulation immediately (ideally within 24 hours of diagnosis)

   • First-line: DOAC
     • Apixaban 10 mg PO BID × 7 days, then 5 mg PO BID (no parenteral lead-in required)
     • OR Rivaroxaban 15 mg PO BID × 21 days, then 20 mg PO daily
   • Alternative: LMWH + warfarin (if DOAC contraindicated)
     • Enoxaparin 1 mg/kg SC q12h
     • Start warfarin 5 mg PO daily (overlap ≥5 days until INR 2-3 × 2 consecutive days)

2. Discontinue oral contraceptive pill immediately

   • COC is contraindicated during and after VTE
   • Counsel on alternative contraception (progesterone-only pill, IUD, barrier methods)

3. Safety netting

   • Advise on signs of PE (chest pain, breathlessness, hemoptysis) → seek urgent care
   • Bleeding precautions on anticoagulation
   • Follow-up in 1-2 weeks (sooner if symptoms worsen)

Disposition:

• Outpatient management appropriate (low-risk DVT, young, no comorbidities, reliable for follow-up)

Q5: How long would you anticoagulate this patient?

A5: VTE Classification: Provoked VTE (estrogen-related; minor persistent risk factor)

Duration:

• 3 months of therapeutic anticoagulation [6]
• Rationale: COC-provoked VTE has intermediate recurrence risk (~5% at 1 year, ~15% at 5 years after stopping anticoagulation); however, risk factor is now removed (discontinued COC), reducing recurrence risk

Reassessment at 3 months:

• If COC permanently discontinued: Stop anticoagulation at 3 months (low recurrence risk)
• If patient wishes to resume estrogen therapy: DO NOT resume; counsel on alternative contraception; consider extended anticoagulation only if other risk factors present

Q6: Would you test for thrombophilia in this patient?

A6: Generally NO — ASH 2023 Guidelines recommend against routine thrombophilia testing after provoked VTE. [10]

Rationale:

• Testing would NOT change management (already treating VTE; COC is sufficient explanation)
• Finding Factor V Leiden or other thrombophilia would not warrant indefinite anticoagulation (provoked event)
• Cost and patient anxiety without benefit

Consider testing ONLY if:

• Strong family history of VTE (first-degree relative with unprovoked VTE at age less than 50)
• Patient planning future pregnancy (may alter pregnancy management if severe thrombophilia)
• Recurrent VTE (this is first event)

Q7: The patient asks if she can ever take the pill again. What would you advise?

A7: Combined oral contraceptive (COC) is absolutely contraindicated after VTE.

Counsel:

• "You've had a blood clot, and the estrogen in the combined pill significantly increases your risk of another clot. We cannot prescribe the combined pill again."
• Safe alternatives:
  • "Progesterone-only pill (POP): Very low VTE risk (comparable to no contraception)"
  • "IUD (hormonal or copper): No VTE risk"
  • "Barrier methods: Condoms"
  • "Implant: Low VTE risk"
• Avoid: Any estrogen-containing contraception (COC, vaginal ring, patch)

---

Viva Scenario 2: Elderly Man with Breathlessness Post-Hip Replacement

Scenario: A 72-year-old man presents with sudden-onset breathlessness 10 days post-total hip replacement. He reports pleuritic chest pain and feels lightheaded. He received prophylactic enoxaparin 40 mg SC daily for 7 days post-surgery (stopped 3 days ago). He mobilized well post-operatively. Past medical history: hypertension, osteoarthritis.

On Examination:

• Vitals: HR 110 bpm, BP 100/65 mmHg, RR 24/min, SpO2 91% on room air (94% on 2L O2), Temp 37.4°C
• Cardiovascular: Tachycardic, JVP not elevated, normal heart sounds
• Respiratory: Clear lung fields, no wheeze, mild right-sided pleuritic pain
• Legs: Right hip surgical scar healing well, no leg swelling or tenderness

Viva Questions & Model Answers:

Q1: What is your diagnosis and immediate management?

A1: Suspected diagnosis: Pulmonary embolism (PE)

Reasoning:

• Post-orthopedic surgery (high VTE risk despite prophylaxis)
• Classic triad: Dyspnea, pleuritic chest pain, tachypnea
• Hypoxemia (SpO2 91%)
• Tachycardia, borderline hypotension

Immediate Management (ABCDE):

1. Airway: Patent
2. Breathing:
   • Oxygen: Already on 2L (SpO2 94%) → continue; titrate to target SpO2 ≥94%
3. Circulation:
   • IV access × 2
   • Fluid challenge: 500 mL crystalloid (cautious; assess response; avoid overload → may worsen RV failure)
   • Monitor: Continuous cardiac monitoring, BP
4. Disability: Alert, anxious
5. Exposure: Full examination (legs for DVT, chest examination)

Q2: How would you risk-stratify this patient for PE?

A2: Wells Score for PE:

• Clinical signs/symptoms of DVT: No = 0 (no leg swelling)
• Alternative diagnosis less likely than PE: Yes = +3 (post-op, classic presentation)
• Heart rate > 100 bpm: Yes = +1.5 (HR 110)
• Immobilization ≥3 days or surgery in previous 4 weeks: Yes = +1.5 (hip replacement 10 days ago)
• Previous DVT/PE: No = 0
• Hemoptysis: No = 0
• Active cancer: No = 0

Total Wells Score: 6 → High probability (PE likely; > 40% prevalence)

Simplified PESI (sPESI) for Risk Stratification:

• Age > 80 years: No = 0
• Cancer: No = 0
• Chronic cardiopulmonary disease: No = 0
• Heart rate ≥110 bpm: Yes = +1 (HR 110)
• SBP less than 100 mmHg: No = 0 (SBP 100, borderline)
• SpO2 less than 90%: Yes = +1 (SpO2 91% on room air)

sPESI = 2 → Not low-risk (30-day mortality ~3-15%; requires hospitalization)

Q3: What investigations would you order?

A3: Given high Wells score (> 4 = "PE likely"):

• Proceed directly to CT Pulmonary Angiography (CTPA)
  • Do NOT do D-dimer (will be positive post-surgery; does not help)

Additional Investigations:

1. Bedside:

   • ECG: Look for sinus tachycardia, S1Q3T3 pattern (classic but insensitive), RBBB, right heart strain
   • ABG: Assess hypoxemia, A-a gradient, exclude alternative diagnoses

2. Bloods:

   • Full blood count, renal function, coagulation screen
   • Troponin: May be elevated (RV strain); prognostic
   • BNP/NT-proBNP: May be elevated (RV dysfunction); prognostic

3. Imaging:

   • CTPA: Definitive (shows filling defect in pulmonary artery)
   • Echocardiography: If stable, assess RV function (RV dilation, RV:LV ratio > 0.9 suggests submassive PE)

4. Leg ultrasound: If CTPA non-diagnostic or contraindicated (may find DVT, which confirms VTE)

Q4: CTPA shows bilateral segmental pulmonary emboli. Troponin is mildly elevated (65 ng/L). Echo shows RV dilation (RV:LV ratio 1.1) with mild RV dysfunction. BP remains 100/65 mmHg. How would you classify and manage this PE?

A4: Classification: Intermediate-Risk (Submassive) PE

Rationale:

• Normotensive (SBP ≥90 mmHg, even if borderline)
• RV dysfunction present (echo: RV dilation, RV:LV > 0.9)
• Myocardial injury present (elevated troponin)
• sPESI ≥1 → Not low-risk

ESC 2019 Classification: [22]

• Intermediate-High Risk (both RV dysfunction AND elevated troponin) → 3-15% 30-day mortality

Management:

1. Anticoagulation (URGENT):

   • Start immediately (do not wait for imaging results if high suspicion)
   • Preferred: Unfractionated heparin (UFH) IV infusion (easier to manage peri-thrombolysis if needed)
     • Bolus: 80 units/kg IV
     • Infusion: 18 units/kg/hr
     • Target aPTT: 1.5-2.5× control (60-80 sec)
   • Alternative (if thrombolysis unlikely): LMWH (enoxaparin 1 mg/kg SC q12h) or DOAC (apixaban/rivaroxaban)

2. Admit to HDU/ICU:

   • Close monitoring (continuous cardiac monitoring, BP, SpO2)
   • Assess for clinical deterioration (worsening hypotension → massive PE)

3. Thrombolysis Decision (Individualized):

   • Not routine for intermediate-risk PE (PEITHO trial: benefit vs. bleeding risk) [26]
   • Consider if:
     • Clinical deterioration (worsening hypotension, increasing oxygen requirement)
     • Extensive clot burden on CTPA
     • Severe RV dysfunction
     • Low bleeding risk (no recent surgery → but this patient is 10 days post-op; moderate bleeding risk)
   • In this case: Thrombolysis NOT recommended (recent major surgery → high bleeding risk; patient stable on anticoagulation)

4. Supportive Care:

   • Oxygen (target SpO2 ≥94%)
   • Fluid management: Cautious (avoid overload → worsens RV function; avoid dehydration → reduces preload)
   • Vasopressors: If hypotension develops (norepinephrine preferred)

5. Disposition:

   • HDU/ICU admission × 24-48 hours (monitor for decompensation)
   • Transition to oral anticoagulation when stable

Q5: The patient stabilizes on heparin. How would you transition to long-term anticoagulation?

A5: Long-Term Anticoagulation Options:

1. Preferred: DOAC (rivaroxaban, apixaban, edoxaban, dabigatran)

   • Apixaban: 10 mg PO BID × 7 days, then 5 mg PO BID
   • Rivaroxaban: 15 mg PO BID × 21 days, then 20 mg PO daily
   • Advantages: No monitoring, predictable, lower bleeding than warfarin
   • Renal function check: Patient's renal function normal → DOAC appropriate

2. Alternative: Warfarin (if DOAC contraindicated or patient preference)

   • Start warfarin 5 mg PO daily
   • Continue heparin overlap ≥5 days until INR 2-3 × 2 consecutive days
   • Target INR: 2-3

Transition:

• Start apixaban (or rivaroxaban) once patient stable (eating, no bleeding, hemodynamically stable)
• Discontinue heparin after first DOAC dose

Q6: How long would you anticoagulate this patient?

A6: VTE Classification: Surgery-Provoked VTE

Duration: 3 months [6]

Rationale:

• Major surgery is a major transient risk factor (strongest provocation)
• Recurrence risk after stopping anticoagulation: Very low (~1% at 1 year, ~3% at 5 years)
• Bleeding risk of indefinite anticoagulation outweighs benefit
• Risk factor removed (surgery > 3 months ago by time of stopping anticoagulation)

Reassessment at 3 months:

• Stop anticoagulation (unless other indications arise)
• Counsel on future VTE prophylaxis (if future surgery, inform anesthetist/surgeon of prior VTE)

Q7: The patient asks why he got a clot despite receiving heparin injections after surgery. What would you explain?

A7: "You received blood-thinning injections (enoxaparin) after surgery to reduce the risk of blood clots. This prophylaxis lowers the risk by about 50-70%, but it doesn't eliminate it completely. Hip replacement is a very high-risk surgery for clots—without prevention, about 40-50% of patients develop clots. With the injections, this drops to about 5-10%.

Unfortunately, you were in that 5-10%. It's not a failure of treatment; it's just that the risk was very high despite prevention.

Also, the injections were stopped 3 days ago, and you developed symptoms 10 days after surgery. Sometimes clots form in the first week (when you were on injections) but don't cause symptoms until later. The prophylaxis you received was appropriate, but no prevention is 100% effective.

The good news is we've caught it early, and with proper treatment, you should make a full recovery."

---

Viva Scenario 3: Unprovoked PE – Duration of Anticoagulation Decision

Scenario: A 58-year-old man completed 6 months of anticoagulation (apixaban) for an unprovoked pulmonary embolism (no surgery, no immobility, no cancer, no travel). He is now asymptomatic. He asks if he can stop his blood thinners. He has no history of bleeding. He is otherwise well (hypertension controlled on amlodipine 5 mg). He lives alone, active lifestyle.

Viva Questions & Model Answers:

Q1: What is the recurrence risk if anticoagulation is stopped?

A1: Unprovoked VTE — Recurrence Risk Off Anticoagulation: [6,9]

• 1 year: ~10%
• 5 years: ~30%
• 10 years: ~40-50%
• Annual risk: ~5-10% per year (highest in first 1-2 years)

Key Point: Unprovoked VTE has a chronic thrombotic tendency (not just a transient event).

Q2: What is the bleeding risk on anticoagulation?

A2: Major Bleeding on Therapeutic Anticoagulation:

• Annual risk: 1-3% per year on DOAC (lower on apixaban ~0.5-1%)
• Fatal bleeding: ~0.2-0.5% per year
• Risk factors for bleeding: Age > 75, prior bleeding, anemia, renal impairment, concomitant antiplatelet agents, falls risk

This Patient's Bleeding Risk:

• Age 58 (not elderly)
• No prior bleeding
• No high-risk features
• Estimated annual major bleeding risk: ~1% (low)

Q3: Would you recommend continuing or stopping anticoagulation?

A3: This is a shared decision-making scenario. Present risks/benefits:

Option 1: Stop Anticoagulation at 6 Months

• Benefit: No bleeding risk, no medication burden
• Risk: 10% recurrence at 1 year, 30% at 5 years
• Recurrent VTE consequences: 1-5% mortality, need for lifelong anticoagulation

Option 2: Continue Anticoagulation Indefinitely

• Benefit: Reduces recurrence risk by ~90% (from 10% to ~1% per year)
• Risk: 1% major bleeding per year (cumulative over years)

Recommendation: Continue Anticoagulation Indefinitely [6,9]

Rationale:

• Male sex: Men with unprovoked VTE have ~10% annual recurrence risk (vs. ~5% in women) [6]
• Low bleeding risk (~1% major bleeding vs. ~10% recurrence)
• Risk-benefit favors continuation: Preventing 9 VTE recurrences per 100 patient-years at a cost of 1 major bleed
• Guidelines (CHEST 2016, ASH 2023): Recommend indefinite anticoagulation for unprovoked VTE if low-moderate bleeding risk, especially in men

Factors Favoring Continuation in This Patient:

• Male sex (higher recurrence risk)
• Age 58 (not elderly; many years of life expectancy)
• Active lifestyle (values preventing recurrence)
• No bleeding risk factors
• First unprovoked PE (if this is proximal DVT or PE, risk higher than distal DVT)

Q4: The patient is concerned about bleeding risk. Are there any alternatives to full-dose anticoagulation?

A4: Yes — Reduced-Dose Extended Prophylaxis:

Option 1: Reduced-Dose Apixaban (Already on apixaban)

• Apixaban 2.5 mg PO BID (vs. standard 5 mg BID)
• AMPLIFY EXTENSION Trial [29]: Reduced recurrence vs. placebo; no increase in major bleeding vs. placebo; non-inferior to standard-dose apixaban for prevention
• Bleeding risk: ~0.5% per year (lower than therapeutic dose)
• Recurrence risk: ~2-3% per year (higher than therapeutic, but lower than no anticoagulation)

Option 2: Reduced-Dose Rivaroxaban (If switch preferred)

• Rivaroxaban 10 mg PO daily (vs. standard 20 mg daily)
• EINSTEIN CHOICE Trial [28]: Reduced recurrence vs. aspirin; similar bleeding to aspirin
• Bleeding risk: ~0.5% per year
• Recurrence risk: ~2-3% per year

Option 3: Aspirin (If patient declines anticoagulation)

• Aspirin 100 mg PO daily
• ASPIRE, WARFASA Trials: Reduces recurrence by ~30% vs. placebo (less effective than anticoagulation)
• Bleeding risk: less than 0.5% per year
• Recurrence risk: ~6-7% per year

Recommendation for This Patient:

• First choice: Continue apixaban 5 mg BID (therapeutic dose; best efficacy, acceptable bleeding risk)
• Alternative (if patient prefers lower bleeding risk): Apixaban 2.5 mg BID (lower bleeding, slightly higher recurrence)
• If declines all anticoagulation: Aspirin 100 mg daily (better than nothing)

Q5: Would you test for thrombophilia?

A5: Consider testing — ASH 2023 Guidelines suggest conditional recommendation for thrombophilia testing in unprovoked VTE. [10]

Rationale for Testing (in Selected Cases):

• May identify severe thrombophilia (antithrombin deficiency, antiphospholipid syndrome, homozygous Factor V Leiden) → warrant indefinite anticoagulation
• May influence family counseling
• May inform decision if bleeding event occurs (severe thrombophilia → resume anticoagulation despite bleeding)

Tests to Consider:

1. Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin IgG/IgM, anti-β2-glycoprotein I IgG/IgM)
   • If positive → Indefinite anticoagulation; warfarin preferred (DOACs inferior in APS) [16]
2. Factor V Leiden mutation (heterozygous vs. homozygous)
3. Prothrombin G20210A mutation
4. Protein C, Protein S, Antithrombin activity (measure off warfarin if possible; DOACs may interfere)

Timing:

• After completing 6 months anticoagulation (or before starting, if suspected)
• Ideally off anticoagulation × 2-4 weeks (but can test on DOAC with chromogenic assays)

Caveat:

• Most inherited thrombophilias do NOT independently change management
  • Heterozygous Factor V Leiden, heterozygous Prothrombin G20210A → Do NOT mandate indefinite anticoagulation (decision based on unprovoked VTE, not thrombophilia)
• Severe thrombophilias (antithrombin deficiency, APS, homozygous FVL, combined thrombophilias) → May warrant indefinite anticoagulation

For This Patient:

• Test if: Patient wants information for decision-making, or if strong family history
• Do NOT test if: Already decided to continue indefinite anticoagulation (result won't change management)

Q6: What would you tell the patient?

A6: "You had a blood clot in your lung 6 months ago. We don't know why it happened—it wasn't triggered by surgery, injury, or other clear cause. This means you have a chronic tendency to form clots.

If we stop your blood thinner, your risk of another clot is about 10% in the first year, and 30% over the next 5 years. That's quite high. Another clot could be serious or even life-threatening.

If we continue your blood thinner, your risk of another clot drops to about 1% per year. The main risk of staying on the blood thinner is bleeding—about 1% per year for major bleeding.

Because you're male, your recurrence risk is higher than average. You're also relatively young and active, so you have many years ahead. The benefit of preventing clots outweighs the bleeding risk.

I recommend continuing your blood thinner indefinitely.

If you're concerned about bleeding, we can reduce the dose (apixaban 2.5 mg twice daily instead of 5 mg), which lowers bleeding risk but still prevents most clots—though not as effectively as the full dose.

What do you think? What matters most to you—preventing another clot, or avoiding bleeding risk? Let's discuss and make a decision together."

Shared Decision-Making:

• If patient chooses: Continue apixaban 5 mg BID → Excellent choice
• If patient chooses: Reduce to apixaban 2.5 mg BID → Acceptable compromise
• If patient chooses: Stop all anticoagulation → Respect decision; offer aspirin 100 mg daily; counsel on signs of VTE recurrence

---

11. Patient Education & Layperson Explanation

What is Venous Thromboembolism (VTE)?

VTE means a blood clot forms in a vein (usually in your leg—called deep vein thrombosis or DVT). Sometimes, part of the clot breaks off and travels to your lungs (called a pulmonary embolism or PE), which can be life-threatening.

Think of it like a dam in a river: The clot blocks blood flow. In your leg, this causes swelling and pain. If the clot travels to your lungs, it blocks oxygen from getting into your blood, causing breathlessness and chest pain.

Why Does This Happen?

Blood clots usually form when:

1. Blood flow slows down (sitting for long periods, after surgery, bedrest)
2. Blood vessels are damaged (surgery, injury, inflammation)
3. Your blood is "stickier" than normal (genetics, cancer, pregnancy, birth control pills)

How Is It Diagnosed?

Your doctor will:

1. Ask about your symptoms and risk factors (recent surgery, long flights, family history)
2. Do a simple blood test (D-dimer) to help rule out a clot if your risk is low
3. Order an ultrasound (for leg clots) or CT scan (for lung clots) to confirm

How Is It Treated?

The main treatment is "blood thinners" (anticoagulants):

• These medicines don't dissolve the clot, but they stop it from getting bigger and prevent new clots
• Your body will naturally dissolve the clot over weeks to months
• Most people take a pill once or twice a day (like apixaban or rivaroxaban)
• You'll need to take this medicine for at least 3 months, sometimes longer or even lifelong (depending on what caused your clot)

In severe cases (massive lung clot causing shock):

• You may get "clot-busting" medicine (thrombolysis) through an IV to quickly dissolve the clot
• This is reserved for life-threatening situations

What to Expect

Recovery:

• Most people feel better within days to weeks
• Leg swelling from DVT may take weeks to months to fully improve
• You'll need regular follow-up to monitor your treatment

Side Effects of Blood Thinners:

• Main risk: Bleeding
  • Nosebleeds, bleeding gums, easy bruising (usually minor)
  • Serious bleeding is rare (~1-3% per year)
• Avoid contact sports and activities with high injury risk
• Tell all your doctors and dentists you're on blood thinners

Long-Term:

• 20-30% of people who have a leg clot develop chronic leg swelling and discomfort (post-thrombotic syndrome)
  • Managed with leg elevation, compression stockings (for comfort), exercise, weight loss
• 2-4% of people who have a lung clot develop chronic lung problems (pulmonary hypertension)
  • Rare; can be treated if detected early

When to Seek Help

Call 999/Emergency Services Immediately if:

• Sudden severe chest pain and difficulty breathing (possible lung clot)
• Coughing up blood
• One leg suddenly becomes very swollen, painful, and blue/purple (possible severe leg clot)
• Fainting or feeling very dizzy
• Heavy bleeding while on blood thinners (vomiting blood, blood in stool/urine, severe headache)

See Your Doctor Soon if:

• New or worsening leg swelling or pain
• Unusual or persistent bleeding (nosebleeds, bleeding gums)
• You miss doses of your blood thinner or have questions about your treatment

How to Prevent VTE

If you're at risk (surgery, long flights, hospitalization):

• Move regularly: Walk around every 1-2 hours on long flights; do ankle pumps if you can't get up
• Stay hydrated
• Compression stockings: May help during travel (but NOT proven to prevent clots after DVT)
• Blood thinner injections or pills: Your doctor may prescribe these after surgery or during hospitalization

General tips:

• Maintain a healthy weight
• Don't smoke
• Stay active
• Tell your doctor if you have a family history of blood clots

Key Takeaways

✅ VTE is serious but very treatable with blood thinners ✅ Most people recover fully with proper treatment ✅ The main risk of blood thinners is bleeding, but serious bleeding is rare ✅ You'll need to take blood thinners for at least 3 months, sometimes longer ✅ Call 999 if you have chest pain and difficulty breathing (possible lung clot)

Remember: If you've had one clot, you're at higher risk for another. Follow your doctor's advice about how long to stay on blood thinners, and report any new symptoms immediately.

---

11. References

Primary Guidelines

1. Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res. 2016;118(9):1340-1347. doi:10.1161/CIRCRESAHA.115.306841

2. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405

3. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510. doi:10.1056/NEJMoa1007903

4. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. doi:10.1056/NEJMoa1302507

5. Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension. Circulation. 2011;123(16):1788-1830. doi:10.1161/CIR.0b013e318214914f

6. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026

7. Righini M, Galanaud JP, Guenneguez H, et al. Anticoagulant therapy for symptomatic isolated distal deep vein thrombosis (CACTUS): a randomised trial. Lancet Haematol. 2016;3(12):e555-e562. doi:10.1016/S2352-3026(16)30131-4

8. Jiménez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010;170(15):1383-1389. doi:10.1001/archinternmed.2010.199

9. Stevens SM, Woller SC, Baumann Kreuziger L, et al. Executive summary: Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):2247-2259. doi:10.1016/j.chest.2021.07.055

10. Connors JM, Levy JH, Middeldorp S, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023;7(22):7101-7138. doi:10.1182/bloodadvances.2023010177

11. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. Thromb Haemost. 2007;98(4):756-764.

12. Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2023;24(2):e334-e347. doi:10.1016/S1470-2045(23)00182-1

13. Boulay F, Berthier F, Schoukroun G, et al. Seasonal variations in hospital admission for deep vein thrombosis and pulmonary embolism: analysis of discharge data. BMJ. 2001;323(7313):601-602. doi:10.1136/bmj.323.7313.601

14. Lidegaard Ø, Løkkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366(24):2257-2266. doi:10.1056/NEJMoa1111840

15. Kuipers S, Cannegieter SC, Middeldorp S, et al. The absolute risk of venous thrombosis after air travel: a cohort study of 8,755 employees of international organisations. PLoS Med. 2007;4(9):e290. doi:10.1371/journal.pmed.0040290

16. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365-1371. doi:10.1182/blood-2018-04-848333

17. Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients' probability of pulmonary embolism. Ann Intern Med. 2000;129(12):1006-1011. doi:10.7326/0003-4819-129-12-200012190-00002

18. Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism. JAMA. 2014;311(11):1117-1124. doi:10.1001/jama.2014.2135

19. van der Hulle T, Cheung WY, Kooij S, et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study). Lancet. 2017;390(10091):289-297. doi:10.1016/S0140-6736(17)30885-1

20. Bates SM, Jaeschke R, Stevens SM, et al. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e351S-e418S. doi:10.1378/chest.11-2299

21. Stein PD, Fowler SE, Goodman LR, et al. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med. 2006;354(22):2317-2327. doi:10.1056/NEJMoa052367

22. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405

23. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S-e496S. doi:10.1378/chest.11-2301

24. Gómez-Outes A, Lecumberri R, Suárez-Gea ML, et al. Case fatality rates of recurrent thromboembolism and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous thromboembolism: a systematic review. J Cardiovasc Pharmacol Ther. 2015;20(5):490-500. doi:10.1177/1074248415575154

25. Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014;311(23):2414-2421. doi:10.1001/jama.2014.5990

26. Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402-1411. doi:10.1056/NEJMoa1302097

27. Zondag W, Mos IC, Creemers-Schild D, et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost. 2011;9(8):1500-1507. doi:10.1111/j.1538-7836.2011.04388.x

28. Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211-1222. doi:10.1056/NEJMoa1700518

29. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708. doi:10.1056/NEJMoa1207541

30. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599-1607. doi:10.1056/NEJMoa1915103

31. Kahn SR, Shapiro S, Wells PS, et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet. 2014;383(9920):880-888. doi:10.1016/S0140-6736(13)61902-9

32. Kaufman JA, Kinney TB, Streiff MB, et al. Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. J Vasc Interv Radiol. 2006;17(3):449-459. doi:10.1097/01.RVI.0000203418.39769.0D

33. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med. 1998;338(7):409-415. doi:10.1056/NEJM199802123380701

34. Kahn SR, Comerota AJ, Cushman M, et al. The post-thrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014;130(18):1636-1661. doi:10.1161/CIR.0000000000000130

35. Vedantham S, Goldhaber SZ, Julian JA, et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med. 2017;377(23):2240-2252. doi:10.1056/NEJMoa1615066

36. Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011;124(18):1973-1981. doi:10.1161/CIRCULATIONAHA.110.015008

37. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e278S-e325S. doi:10.1378/chest.11-2404

38. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e195S-e226S. doi:10.1378/chest.11-2296

39. National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. NICE guideline [NG158]. 2020. https://www.nice.org.uk/guidance/ng158

---

Last Reviewed: 2026-01-10 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and local guidelines. Always consult appropriate specialists and refer to the most current evidence. This information is not a substitute for professional medical judgment, diagnosis, or treatment. In acute emergencies, activate appropriate emergency response systems immediately.